WO2000076537A2 - Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases - Google Patents
Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases Download PDFInfo
- Publication number
- WO2000076537A2 WO2000076537A2 PCT/US2000/011008 US0011008W WO0076537A2 WO 2000076537 A2 WO2000076537 A2 WO 2000076537A2 US 0011008 W US0011008 W US 0011008W WO 0076537 A2 WO0076537 A2 WO 0076537A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- peptide
- vims
- isolated
- env
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 86
- 201000011510 cancer Diseases 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title description 24
- 230000003612 virological effect Effects 0.000 title description 15
- 201000010099 disease Diseases 0.000 title description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 492
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 289
- 230000004927 fusion Effects 0.000 claims abstract description 129
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 97
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 230000002163 immunogen Effects 0.000 claims abstract description 55
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims abstract description 28
- 201000001441 melanoma Diseases 0.000 claims abstract description 26
- 241000712431 Influenza A virus Species 0.000 claims abstract description 22
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 20
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 20
- 241000712079 Measles morbillivirus Species 0.000 claims abstract description 20
- 241000701806 Human papillomavirus Species 0.000 claims abstract description 19
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 14
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 11
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 8
- 201000005202 lung cancer Diseases 0.000 claims abstract description 8
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 8
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 7
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 7
- 206010042971 T-cell lymphoma Diseases 0.000 claims abstract description 7
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims abstract description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 7
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 7
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 7
- 208000032839 leukemia Diseases 0.000 claims abstract description 7
- 201000007270 liver cancer Diseases 0.000 claims abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 175
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 84
- 229930193140 Neomycin Natural products 0.000 claims description 39
- 241000700605 Viruses Species 0.000 claims description 39
- 229960004927 neomycin Drugs 0.000 claims description 39
- 210000000265 leukocyte Anatomy 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 34
- 239000003937 drug carrier Substances 0.000 claims description 32
- 230000002950 deficient Effects 0.000 claims description 26
- 208000031886 HIV Infections Diseases 0.000 claims description 16
- 208000037357 HIV infectious disease Diseases 0.000 claims description 14
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 14
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 208000005176 Hepatitis C Diseases 0.000 claims 10
- 208000002672 hepatitis B Diseases 0.000 claims 10
- 208000037797 influenza A Diseases 0.000 claims 10
- 208000003154 papilloma Diseases 0.000 claims 10
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 89
- 239000000427 antigen Substances 0.000 description 97
- 108091007433 antigens Proteins 0.000 description 97
- 102000036639 antigens Human genes 0.000 description 97
- 239000002609 medium Substances 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 35
- 230000000735 allogeneic effect Effects 0.000 description 34
- 210000004881 tumor cell Anatomy 0.000 description 34
- 230000009089 cytolysis Effects 0.000 description 32
- 210000004754 hybrid cell Anatomy 0.000 description 31
- 230000004044 response Effects 0.000 description 30
- 208000030507 AIDS Diseases 0.000 description 29
- 230000000890 antigenic effect Effects 0.000 description 27
- 238000002347 injection Methods 0.000 description 27
- 239000007924 injection Substances 0.000 description 27
- 239000012636 effector Substances 0.000 description 25
- 206010022000 influenza Diseases 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 22
- 210000004698 lymphocyte Anatomy 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 20
- VYZAMTAEIAYCRO-BJUDXGSMSA-N Chromium-51 Chemical compound [51Cr] VYZAMTAEIAYCRO-BJUDXGSMSA-N 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 239000012981 Hank's balanced salt solution Substances 0.000 description 18
- 108010002350 Interleukin-2 Proteins 0.000 description 18
- 102000000588 Interleukin-2 Human genes 0.000 description 18
- 239000006285 cell suspension Substances 0.000 description 18
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000003013 cytotoxicity Effects 0.000 description 17
- 231100000135 cytotoxicity Toxicity 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 230000001404 mediated effect Effects 0.000 description 17
- 229920001223 polyethylene glycol Polymers 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 229960005486 vaccine Drugs 0.000 description 17
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 16
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 15
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 11
- 230000000961 alloantigen Effects 0.000 description 11
- 230000005951 type IV hypersensitivity Effects 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 208000023275 Autoimmune disease Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000002269 spontaneous effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- 230000007910 cell fusion Effects 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000007717 exclusion Effects 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 229960004857 mitomycin Drugs 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 6
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 230000004940 costimulation Effects 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 239000006152 selective media Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 229960003896 aminopterin Drugs 0.000 description 5
- 230000036436 anti-hiv Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000007402 cytotoxic response Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229960001936 indinavir Drugs 0.000 description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 229940117681 interleukin-12 Drugs 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 229920001917 Ficoll Polymers 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 208000005647 Mumps Diseases 0.000 description 4
- 238000011225 antiretroviral therapy Methods 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000009795 derivation Methods 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 208000010805 mumps infectious disease Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229960000884 nelfinavir Drugs 0.000 description 4
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 102000043276 Oncogene Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000007503 antigenic stimulation Effects 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 230000004073 interleukin-2 production Effects 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 206010060935 Alloimmunisation Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 2
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- -1 gp75 Proteins 0.000 description 2
- 108010007811 human immunodeficiency virus p17 gag peptide Proteins 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 108010061181 influenza matrix peptide (58-66) Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000739160 Homo sapiens Secretoglobin family 3A member 1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000411349 Macruromys major Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100037268 Secretoglobin family 3A member 1 Human genes 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007893 endotoxin activity Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000003237 recreational drug Substances 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
Definitions
- the present invention relates to the field of treatment of cancer, Acquired Immune Deficiency Syndrome (AIDS) and other viral diseases.
- the present invention provides a method of immunotherapy for the treatment of cancer, AIDS and other viral diseases.
- Alloimmunization would represent a unique IBT strategic approach because: 1) PBMC from a higher percentage of HIV + patients generated in vitro Th responses to allogeneic PBMC than to recall antigens (29); 2) Th cell defects for generating influenza A virus (FLU)-specific CTL in AIDS patients was circumvented by in vitro costimulation of patients' PBMC with FLU plus allogeneic PBMC (30); and 3) APC from uninfected allogeneic donors can provide a source of APC with intact antigen-presenting molecules and function that are deficient in some HIV ⁇ patients (31).
- costimulation of AIDS patients' PBMC with allogeneic cells and HIN antigens to generate HIV-specific cellular immunity has not been investigated.
- Allo-specific help might be most effective in the patient if the same APC that presents the HIN peptide to the T effector cell (Te) also presents MHC alloantigens to the alloantigen-specific Th cell (27).
- An APC presenting both helper and effector antigens might provide a better chance for Th cytokines to enhance the HIV-specific Te function, because these two interacting T cells would be necessarily activated by a common APC in the same microenvironment. This strategy could provide optimal interaction among Th, APC and CTL (three-cell model) (27, 32-34).
- the present invention provides a composition comprising a semi-allogeneic hybrid fusion cell and an immunogenic peptide. Further provided is a composition comprising isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8 and isolated env PI 8 MN.
- composition comprising isolated nef, isolated gag and isolated Tat is also provided.
- composition comprising isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8, isolated env PI 8 MN, isolated nef, isolated gag and isolated Tat.
- composition comprising at least two isolated peptides selected from the group consisting of isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8, isolated env PI 8 MN, isolated nef, isolated gag and isolated Tat.
- the present invention provides a method of treating an HIV infection in a subject, comprising administering to the subject an effective amount of an immunogenic HlV-specific peptide in a pharmaceutically acceptable carrier and an effective amount of a hybrid fusion cell in a pharmaceutically acceptable carrier, wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell from the subject.
- the present invention provides a composition comprising isolated immunogenic peptides of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- composition comprising a semi- allogeneic hybrid fusion cell and an immunogenic peptide of a virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- a virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- the present invention further provides a composition comprising cancer- specific immunogenic peptides selected from the group consisting of B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer in a pharmaceutically acceptable carrier.
- cancer-specific immunogenic peptides selected from the group consisting of B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer in a pharmaceutically acceptable carrier.
- the present invention also provides a method of treating cancer in a subject, comprising administering to the subject an effective amount of an cancer-specific immunogenic peptide in a pharmaceutically acceptable carrier and an effective amount of a hybrid fusion cell in a pharmaceutically acceptable carrier, wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell from the subject.
- Fig. 1 shows the survival curve of FO-l-neo cells exposed to increasing doses of ⁇ -rays.
- Fig. 2 shows the surface expression of HLA class I antigens on parental cells (FO-1 #12 and 501) and on tumor cell hybrids (FO-1 #12 X 501) obtained from their fusion. Single-cell suspensions from each culture (indicated at the side of the figure ) were subjected to indirect immunofluorescent staining and reacted with second antibody alone (blank), monoclonal antibody (mAb) W6-32 (anti-HLA-A,B,C + ⁇ 2 microglobulin), and mAb PA2.1 (anti-HLA-A2).
- mAb monoclonal antibody
- Fluorescence intensity was determined by flow cytometry on a Becton-Dickinson cell analyzer. Note that FO-1 clone 12 (FO-1) cells do not express HLA class I antigens because they lack ⁇ 2 microglobulin expression; in contrast, tumor cell hybrids (FO-1 #12 X 501) grown in selective medium containing HAT and the neomycin analog G418 (600 ⁇ g/ml) express on the cell surface HLA class I antigens, including HLA-A2 (this antigen derives from 501 parental cells).
- Fig. 3 shows the survival curve of 2 melanoma hybrids (FO-1 #12 x WM2; FO- 1 #12 x JJ) exposed to ⁇ -rays.
- Fig. 4 shows proliferative responses of PBMC from HIV + patients stimulated with semi-allogeneic hybrids and with the allogeneic FOl-12 line.
- PBMC from three HIV + patients (#6, #3 and #1) were stimulated for 5 days with irradiated (25 Gy) donor- derived semi-allogeneic hybrids or the allogeneic line FOl-12 or ewv peptide pool.
- Fig. 5 shows IL-2 production and env-specific CTL generation comparing semi- allogeneic hybrids that were irradiated (irrad) with those that were treated with mitomycin C (MMC).
- A IL-2 production by untreated hybrid , irrad hybrid , or MMC treated.
- B generation of e «v-specif ⁇ c CTL by co-stimulation with env peptides plus hybrids that were irradiated ( O) or treated with MMC ( •) before co-culturing with PBMC and env peptides.
- Fig. 6 shows CTL activity generated by donor PBMC stimulated with semi-allogeneic hybrids (PBMC+hyb), PBMC stimulated with hybrids plus env peptide pool (PBMC+hyb+env) or env pool alone (PBMC+env).
- the CTL effectors generated were assayed on autologous EBV-transformed targets pulsed with env peptide pool (upper panels) or with media alone (lower panels).
- Patients #1, #3, #4, and #6 represent the responses observed by PBMC from 4/6 WYA patients tested.
- Patients #3, #4, and #6 illustrate the data from the three CTL responders; patient #1 shows negative data representative of the three CTL non-responders.
- Fig. 7 shows PBMC from patients #3 (that contain both T cells and autologous APC) were stimulated: with envelope peptides (env) in culture for 6 days ( • ); by the pulsing PBMC with env for 1 hr, followed by washing out env and 6 days in culture ( O ); with env plus hybrid cells (hyb) for 6 days ( ⁇ ); by pulsing the PBMC with env for 1 hr, followed by washing out env and adding hyb for 6 days ( D ); by pulsing hyb cells with env for 1 hr, followed by washing out env and adding PBMC for 6 days ( ⁇ ); or by co-culture of PBMC with hyb alone (negative control) ( ⁇ ).
- envelope env envelope peptides
- Fig. 8 shows models illustrating the interaction between: (A) semi-allogeneic (hybrid) APC that stimulate allo-specific T helper cells via allo-MHC (class II) and autologous APC expressing e «v+self-MHC (class I) that stimulate env-specific CTL precursors ; and (B) semi-allogeneic hybrid APC that concomitantly stimulate allo- specific T helper cells via allo MHC (class II) and env-specific CTL precursors via ewv+self-MHC (class I).
- Fig. 9 shows CTL activity of donor PBMC stimulated with semi-allogeneic hybrids (RC+semiallo), hybrids plus env peptide pool (RC+semiallo+env), or env pool alone (RC+env).
- the CTL effectors generated were assayed on autologous EBV- transformed targets pulsed with env peptide pool (upper panels) or with media alone (lower panels).
- Patients #1 (panel B), #3 (panel A), #4 (panel D), and #6 (panel C) represent the responses observed by PBMC from four of six HIV + patients tested.
- Patients #3 (panel A), #4 (panel D), and #6 (panel C) illustrate the data from the three CTL responses; patient #1 (panel B) shows negative data representative of the three CTL non-responders.
- Fig. 10 shows CTL activity by a patient's (#3) PBMC stimulated by: pulsing the PBMC with env peptides for 1 hr before six day culture (RC+env*); PBMC in culture with env for six days (RC+env); PBMC in culture with env and hybrids for six days (RC+env+hyb); pulsing of PBMC with env before adding hybrid cells for six days (RC+env*+hyb); pulsing of hybrid cells with env before adding PBMC for six days (RC+hyb+env*); PBMC in culture for six days with hybrid cells (RC+hyb).
- Fig. 11 shows results of cytotoxicity assays ( 51 Cr release) showing % lysis values of T2 target cells loaded with HL A- A2 -restricted exogenous peptides (FLU-MI or HIV- 1 -derived GAG). Unloaded T2 cells and Daudi cells were used as controls.
- Each panel (A-F) represents PBMC effector cells from an HIV-infected, HLA-A2 + patient that have been exposed to: A) no antigen; B) irradiated, semi-allogeneic hybrids (HYB); C) FLU-MI peptide; D) FLU-MI peptide plus irradiated, semi-allogeneic hybrids; E) GAG peptide; or F) GAG peptide plus irradiated, semi-allogeneic hybrids. Lysis with effecto ⁇ target ratios of 1 : 1 and 5:1 are shown.
- a may mean one or more.
- a cell may mean one cell or more than one cell.
- the cell may mean one or more than one cell.
- the present invention provides a composition comprising a semi-allogeneic hybrid fusion cell and an immunogenic peptide.
- the immunogenic peptide for example, can be a virus-specific peptide or a cancer-specific peptide specific for a cancer.
- the hybrid fusion cell is a fusion cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a cell of a human subject.
- the cell originates from one subject and is used to produce the hybrid fusion cell of the present invention for the treatment of the same subject diagnosed with cancer, AIDS or other viral diseases.
- the cell can be, for example, a peripheral blood mononuclear cell (PBMC), such as a lymphocyte or a monocyte.
- PBMC peripheral blood mononuclear cell
- the PBMC is usually a cell that is not infected by a virus.
- the cell can come from a subject who does not have cancer, AIDS or other viral diseases for future use in a hybrid fusion cell.
- the present invention provides a composition comprising a semi-allogeneic hybrid fusion cell and an isolated HlV-specific peptide.
- the hybrid fusion cell is a fusion of the FO-1 #12 cell, described below, and a PBMC derived from an HIV- positive subject.
- the present invention provides a composition wherein the hybrid fusion cell presents a virus-specific immunogenic peptide.
- presents is meant that the hybrid fusion cell acts like an antigen presenting cell.
- the hybrid fusion cell ingests a foreign antigen and/or displays the foreign antigen bound to a class II MHC protein on its surface.
- the subject's helper T cells bind to the foreign antigen bound to a class II MHC protein and become activated, subsequently activating cytotoxic T cells by secreting cytokines, such as interleukins.
- the present invention provides a composition wherein the hybrid fusion cell presents an isolated immunogenic HIV-specific peptide.
- isolated as used herein means the peptide of this invention is sufficiently free of contaminants or cell components with which peptides normally occur and is present in such concentration as to be the only significant peptide present in the sample. "Isolated” does not mean that the preparation is technically pure (homogeneous), but it is sufficiently pure to provide the peptide in a form in which it can be used therapeutically.
- an isolated HIV-specific peptide is free of other peptides and nucleic acids comprising HIV.
- immunogenic means able to produce an immune response in a subject.
- An HIV-specific peptide can be an envelope peptide or a core peptide.
- isolated HIV-specific envelope peptides include, but are not limited to, isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8 and isolated env PI 8 MN.
- isolated HIV-specific core peptides include, but are not limited to, isolated nef, isolated gag and isolated Tat.
- the present invention thus provides a composition comprising the hybrid fusion cell and an isolated HIV-specific envelope peptide, wherein the envelope peptide is selected from the group consisting of isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8 and isolated env PI 8 MN.
- the present invention provides a composition comprising the hybrid fusion cell and at least two isolated peptides selected from the group consisting of isolated env Tl, isolated env T2, isolated env Th4.1, isolated env P18 and isolated env PI 8 MN.
- the present invention provides a composition comprising isolated env Tl, isolated env T2, isolated env Th4.1, isolated env PI 8 and isolated env PI 8 MN.
- the present invention provides a composition comprising the hybrid fusion cell of the invention and at least two isolated peptides selected from the group consisting of nef, gag and Tat.
- the present invention further provides a composition comprising isolated nef, isolated gag and isolated Tat. Moreover, the present invention provides a composition comprising isolated env Tl, isolated env T2, isolated env Th4.1, isolated env P18, isolated env PI 8 MN, isolated nef, isolated gag and isolated Tat. The present invention also provides a composition comprising at least two isolated peptides selected from the group consisting of isolated env Tl, isolated env T2, isolated env Th4.1, isolated env P18, isolated env P18 MN, isolated nef, isolated gag and isolated Tat.
- the present invention provides a composition comprising a semi- allogeneic hybrid fusion cell and an isolated immunogenic peptide of a virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- a peptide can be isolated from the wild virus.
- a peptide can be produced when the sequence of the nucleic acid encoding the amino acid sequence of the peptide is known.
- a person of skill in the art can express the product of the nucleic acid sequence by genetic engineering methods known in the art.
- a person of skill in the art can synthesize an isolated peptide of a virus by chemical means when the amino acid sequence comprising the peptide is known.
- the present invention provides a composition wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell derived from a subject infected with a virus selected from the group consisting of HTLV-1 , Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- the hybrid fusion cell is the cell as described below.
- the present invention provides a composition wherein the hybrid fusion cell presents a virus-specific immunogenic peptide.
- the hybrid fusion cell acts as an antigen-presenting cell.
- virus-specific immunogenic peptides include, but are not limited to, those peptides of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- the present invention further provides a composition comprising a hybrid fusion cell and a virus-specific immunogenic peptide, wherein the virus-specific immunogenic peptide is selected from the group consisting of an isolated peptide of HTLV-1, an isolated peptide of Hepatitis B virus, an isolated peptide of Hepatitis C virus, an isolated peptide of rubeola virus, an isolated peptide of influenza A virus and an isolated peptide of Human Papilloma Virus.
- the virus-specific immunogenic peptide is selected from the group consisting of an isolated peptide of HTLV-1, an isolated peptide of Hepatitis B virus, an isolated peptide of Hepatitis C virus, an isolated peptide of rubeola virus, an isolated peptide of influenza A virus and an isolated peptide of Human Papilloma Virus.
- the present invention provides a composition comprising a fusion hybrid cell and at least two isolated peptides selected from the group consisting of a peptide of HTLV-1, a peptide of Hepatitis B virus, a peptide of Hepatitis C virus, a peptide of rubeola virus, a peptide of influenza A virus and a peptide of Human Papilloma Virus.
- the present invention further provides a composition comprising isolated peptides of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus in a pharmaceutically acceptable carrier.
- the present mvention provides a composition comprising a population of PBMCs enriched for cytotoxic T cells produced by the method of the invention.
- the cytotoxic T cells are directed toward the immunogenic peptides that the hybrid fusion cell presents.
- composition comprising a population of peripheral blood mononuclear cells enriched for cytotoxic T cells produced by the method as described below is provided.
- the composition can be in a pharmaceutically acceptable carrier.
- the present invention further provides a composition comprising a semi- allogeneic hybrid fusion cell and an immunogenic cancer-specific peptide.
- the cancer- specific immunogenic peptide can be from any cancer including, but not limited to, B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer.
- immunogenic cancer-specific peptides include any tumor antigen now known or later identified as a tumor antigen.
- the tumor antigen can be, but is not limited to, human epithelial cell mucin (Muc-1 ; a 20 amino acid core repeat for Muc-1 glycoprotein, present on breast cancer cells and pancreatic cancer cells), the Ha-ras oncogene product, p53, carcino-embryonic antigen (CEA), the raf oncogene product, GD2, GD3, GM2, TF, sTn, MAGE-1, MAGE-3, tyrosinase, gp75, Melan-A/Mart-l, gplOO, HER2/neu, EBV-LMP 1 & 2, HPV-F4, 6, 7, prostatic serum antigen (PSA), alpha-fetoprotein (AFP), CO17-1A, GA733, gp72, p53, the ras oncogene product, HPV E7 and melanoma gangliosides, as well as any other tumor antigens now known or identified in the future.
- the present invention provides a composition comprising cancer- specific immunogenic peptides selected from the group consisting of B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer in a pharmaceutically acceptable carrier.
- cancer-specific immunogenic peptides selected from the group consisting of B cell lymphoma, T cell lymphoma, myeloma, leukemia, breast cancer, pancreatic cancer, colon cancer, lung cancer, renal cancer, liver cancer, prostate cancer, melanoma and cervical cancer in a pharmaceutically acceptable carrier.
- the present invention provides a population of PBMCs enriched for cytotoxic T cells produced by the method of the present invention.
- the PBMCs can be in a pharmaceutically acceptable carrier.
- the present invention provides a method of enhancing the cytotoxic T cell activity of a population of peripheral blood mononuclear cells of a human subject, comprising contacting the peripheral blood mononuclear cells (PBMCs) of the subject with a composition comprising a hybrid fusion cell and an immunogenic peptide.
- the immunogenic peptide can be a virus-specific peptide, such as an HIV- specific peptide.
- HIV-specific peptides include, but are not limited to, isolated env Tl, isolated env T2, isolated env Th4.1, isolated env P18, isolated env P18 MN, isolated nef, isolated gag and isolated Tat.
- the contacting step can occur in vitro or in vivo.
- the contacting step occurs in vitro, sufficient time is allowed to increase the numbers and cytotoxic activity of CTL in the population.
- the amount of time may vary but is expected to be in the range of one to two weeks.
- An example of this method is provided in the Examples herein.
- the contacting step occurs in vivo, it follows the concurrent administration of the hybrid fusion cell and peptide combination as described in the Examples herein.
- the present invention provides a method of treating a viral infection in a subject, comprising administering to the subject an effective amount of a composition of the present invention comprising a population of PBMCs enriched for cytotoxic T cells produced as described below, in a pharmaceutically acceptable carrier.
- a composition of the present invention comprising a population of PBMCs enriched for cytotoxic T cells produced as described below, in a pharmaceutically acceptable carrier.
- HIV infection an example of a viral infection that can be treated according to the method of the present invention is HIV infection.
- the present invention further provides a method of treating an HIV infection in a subject, comprising administering to the subject an effective amount of the hybrid fusion cell of the present invention and an effective amount of at least one isolated immunogenic HIV-specific peptide in a pharmaceutically acceptable carrier.
- an "effective amount" of an agent is that amount needed to achieve the desired result or results.
- a therapeutically effective amount of the composition of the present invention can decrease viral load, increase CD4 + counts and restore CTL function to counter the HIV.
- compositions of this invention can comprise a pharmaceutically acceptable carrier.
- the present invention provides a method of treating an HIV infection in a subject, comprising administering to the subject an effective amount of an HIV-specific peptide in a pharmaceutically acceptable carrier and an effective amount of a hybrid fusion cell in a pharmaceutically acceptable carrier, wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell derived from the subject.
- the hybrid fusion cell and the HIV-specific peptide are administered conc rently as described in the Examples herein.
- At least one of the following isolated HIV-specific peptides is a component of the composition which is administered to the subject: env Tl, env T2, env Th4.1, env P 18 and en v P 18 MN, nef, gag and Tat.
- the present invention provides a method enhancing the cytotoxic T cell activity of a population of peripheral blood mononuclear cells of a subject infected with at least one virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus, comprising contacting the peripheral blood mononuclear cells with a hybrid fusion cell of the present invention and an immunogenic peptide of a virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus.
- the contacting can occur in vitro or in vivo.
- the present invention provides a method of treating a subject infected with a least one virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus, comprising administering to the subject an effective amount of the composition comprising a population of PBMCs enriched for cytotoxic T cells in a pharmaceutically acceptable carrier.
- the cytotoxic T cells are directed toward the immunogenic peptide of the virus that infects the subject.
- Also provided is a method of treating a subject infected with at least one virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus comprising administering to the subject an effective amount of a composition comprising a semi-allogeneic hybrid fusion cell and an isolated peptide of a virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus in a pharmaceutically acceptable carrier.
- a method of treating a subject infected with at least one virus selected from the group consisting of HTLV-1, Hepatitis B virus, Hepatitis C virus, rubeola virus, influenza A virus and Human Papilloma Virus comprising administering to the subject an effective amount of an isolated immunogenic virus- specific peptide selected from the group consisting of a peptide of HTLV- 1 , a peptide of Hepatitis B virus, a peptide of Hepatitis C virus, a peptide of rubeola virus, a peptide of influenza A virus and a peptide of Human Papilloma Virus in a pharmaceutically acceptable carrier and an effective amount of a hybrid fusion cell in a pharmaceutically acceptable carrier wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell of the subject infected by a virus.
- the dosage regimen is
- the present invention provides a method of enhancing the cytotoxic T cell activity of a population of peripheral blood mononuclear cells of a human subject, comprising contacting the peripheral blood mononuclear cells of the subject with the hybrid fusion cell of the present invention and an immunogenic cancer-specific peptide.
- the contacting can be in vitro or in vivo.
- the cytotoxic T cells that are enhanced in activity are directed toward an immunogenic cancer-specific peptide.
- the present invention provides a method of treating cancer in a human subject, comprising administering to the subject an effective amount of a composition of cytotoxic T cells with enhanced activity directed toward an immunogenic cancer-specific peptide in a pharmaceutically acceptable carrier.
- the present invention provides a method of treating cancer in a subject, comprising administering to the subject an effective amount of a cancer- specific immunogenic peptide in a pharmaceutically acceptable carrier and an effective amount of a hybrid fusion cell in a pharmaceutically acceptable carrier, wherein the hybrid fusion cell is a fusion of a cell that is deficient in ⁇ 2 microglobulin, resistant to neomycin and sensitive to HAT and a white blood cell from the subject.
- the immunogenic cancer-specific peptide and the hybrid fusion cell can be administered to the subject concurrently.
- compositions of the present invention can be administered to a subject by parenteral routes of administration which include, but are not limited to, intravenously, intramuscularly, intradermally, subcutaneously, intraperitoneally and intrathecally.
- the invention provides "allo" cells capable of fusing with patient-derived cells to form semi-allogeneic cell hybrids.
- a "patient-derived” cell is a cell from a subject who will receive fusion cells of this invention.
- the allo cell provided herein is the fusion partner of a patient ("self) cell in the present semiallogeneic cell hybrids.
- the allo cell of the present invention is an isolated cell or cell line, wherein the cell is deficient in ⁇ 2 microglobulin, has a selectable dominant marker and a selectable recessive marker.
- the cell or cell line is preferably human, or human-derived. An example of a cell having these characteristics is the cell line designated FO-1 #12.
- the allo cell or cell line as described, wherein the dominant marker, drug or antibiotic resistance, is provided.
- the antibiotic resistance can be, for example, to neomycin or to any other drug or antibiotic resistance marker as is well known in the art.
- a selectable dominant marker associated with resistance to drug/antibiotic other than neomycin hygromycin, methotrexate, c -amanitin, ouabain, etc.
- the allo cell or cell line as described, wherein the recessive marker is sensitivity to aminopterin-containing medium (sensitivity to hypoxanthine + aminopterin + thymidine (HAT)-containing medium) is provided.
- HAT hypoxanthine + aminopterin + thymidine
- recessive selectable markers such as deficiency in thymidine kinase.
- the cell FO-1 #12 is characterized as being ⁇ 2 microglobulin deficient, neomycin-resistant and HAT-sensitive.
- An example of a method for making such a cell is given in the Examples herein.
- a cell having the characteristics of the cell line designated FO-1 #12 and deposited on August 27, 1996 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 under accession number ATCC CRL-12177 is also provided.
- an allo cell of the invention wherein the cell expresses a heterologous antigen.
- the antigen when expressed, can be presented at least in part on the surface of a cell, bound to an HLA class I molecule.
- the heterologous antigen need not be thought of as a typical cell surface antigen.
- PSA prostate-specific antigen
- the allo cell can express a heterologous nucleic acid encoding an antigen that is a tumor antigen.
- the heterologous nucleic acid is introduced into the allo cell by methods well known in the art, such as transfection or transduction.
- the tumor antigen of this invention can be gpl00/pmell7 (which is constitutively expressed by FO-1 #12), carcino-embryonic antigen (CEA), MUC-1, HER-2/neu, MAGE-1, MAGE-3, BAGE, GAGE, tyrosinase, MART-1, gp75, MUM, HPV-16, prostate-specific antigen (PSA), and other breast cancer-specific antigens, colon cancer-specific antigens, lung cancer- specific antigens, pancreatic cancer-specific antigens, prostate cancer-specific antigens, HPV-specific antigens (23), or other antigens.
- the allo cell can express a virus-specific antigen.
- the cell can express an HIV-specific antigen.
- the HIV-specific antigen can, for example, be gag or an antigenic fragment thereof, pol or an antigenic fragment thereof, env or an antigenic fragment thereof or nef or an antigenic fragment of it (24, 25).
- a cell expressing a polypeptide fragment of the heterologous antigen is also provided.
- This cell can be the allo cell that will be fused to the patient cell.
- fragment as used herein regarding antigens, means a molecule of at least 5 contiguous amino acids that has an antigenic function as described herein.
- “specific” means that the amino acid sequence is not found identically in any other source.
- virus-specific e.g., HIV-specific
- An antigenic fragment can be selected by applying the routine technique of epitope mapping to the larger antigen to determine the regions of the proteins that contain epitopes that are capable of eliciting an immune response in an animal.
- an antigenic polypeptide containing the epitope can be synthesized directly, or produced recombinantly by cloning nucleic acids encoding the polypeptide in an expression system, according to the standard methods.
- an antigenic fragment of the antigen can be isolated from the whole antigen or a larger fragment by chemical or mechanical disruption. Fragments can also be randomly chosen from a known antigen sequence and synthesized. The purified fragments thus obtained can be tested to determine their antigenicity and specificity by routine methods or by the TIL/PBMC education methods described herein.
- the heterologous antigenic polypeptides to be expressed in the present cells can be tested to determine their immunogenicity and specificity. Briefly, B lymphocytes and T cells are isolated from a patient who has an immune response to the present vaccine. The peptides expressed by the vaccine are stripped off of the vaccine cells and loaded onto B cells. Patient T cells are then tested for their ability to kill the B cells loaded with the vaccine peptides. If the T cells kill the B cells, the peptide antigen(s) eliciting the response are purified and sequenced. By identifying the peptide, synthetic vaccines can be generated.
- a nucleic acid encoding a particular antigen of interest, or a region of that nucleic acid can be constructed, modified, or isolated. That nucleic acid can then be cloned into an appropriate vector, which can direct the expression of the antigen in the allo cell.
- the vector is contemplated to have the necessary functional elements that direct and regulate transcription of the inserted gene, or hybrid gene.
- These functional elements include, but are not limited to, a promoter, regions upstream or downstream of the promoter, such as enhancers that may regulate the transcriptional activity of the promoter, an origin of replication, appropriate restriction sites to facilitate cloning of inserts adjacent to the promoter, antibiotic resistance genes or other markers which can serve to select for cells containing the vector or the vector containing the insert, RNA splice junctions, a transcription termination region, or any other region which may serve to facilitate the expression of the inserted gene or hybrid gene.
- the vector can be delivered to the cell for expressing the antigen-encoding nucleic acid using commercially available systems as further described below and in the literature. Cell Hybrids.
- a cell hybrid formed by the fusion between the allo cell (e.g., an FO-1 #12 cell or other cell described herein) and a mammalian cell is provided.
- the fusion can take place under any conditions suitable for such fusions.
- One set of conditions under which cell fusion take place is described in the Examples herein. It is recognized, however, that other conditions are known or can be derived that permit fusion, and this does not change the nature of the resulting hybrid.
- the mammalian cell can be a cell of a human subject.
- the human cell can be a white blood cell.
- the white blood cell can be a lymphocyte or a monocyte.
- the cell of a human subject can be a tumor cell.
- the tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, prostatic carcinoma etc.
- a fused cell hybrid of the heterologous antigen-expressing cell (allo-antigen cell) of the invention and a mammalian cell is provided.
- a cell hybrid wherein the mammalian cell is a patient-derived human cell is provided.
- the patient-derived human cell can be a white blood cell, more conveniently a peripheral white blood cell.
- "patient-derived” means of or originating from a patient.
- the heterologous antigen-expressing cell can express a tumor antigen.
- the heterologous antigen-expressing cell can express an HIV- or HPV-specific antigen.
- the semi-allogeneic vaccine of this invention comprises three components: 1) a "self component represented by the patient-derived (-specific) HLA haplotype; 2) an "allo” component represented by any human cell line which has a different HLA haplotype; and 3) an "antigen" component which is disease-specific and may or may not be patient-derived.
- the antigen is an immunogenic virus-specific peptide or cancer-specific peptide specific for a cancer.
- the immunogenic peptide can be from a virus or cancer cell or synthesized by methods known to persons of skill in the art.
- the allo and antigen components are engineered into an appropriately modified human cell line (e.g., a cell having the characteristics of FO-1 #12) which is fused with the patient-derived self component in order to generate patient-tailored semi-allogeneic cell hybrids.
- an appropriately modified human cell line e.g., a cell having the characteristics of FO-1 #12
- peripheral white blood cells e.g., peripheral white blood cells
- An appropriate isolated peptide or engineered antigen component can be virus- or cancer-specific, for example, HIV-derived gag protein product (peptide or polypeptide) for preventive, as well as therapeutic AIDS vaccines; carcino-embryonic antigen (CEA) for preventive as well as therapeutic vaccination against many forms of carcinoma (colon, breast, lung, pancreatic, etc.); gp 100 for preventive as well as therapeutic vaccination against melanoma; and prostate-specific antigen (PSA) for preventive as well as therapeutic vaccination against prostatic cancer.
- the genetic engineering involved in producing the engineered allo/antigen cell of the hybrid is routine and can be accomplished using commercially available vectors and other reagents. The method of fusing the allo/antigen cell and the self cell to form the hybrid is also routine and described herein.
- the cell hybrid provided herein can be lethally irradiated for use as a preventive or therapeutic vaccine for cancer or AIDS.
- the irradiation step takes place shortly before administration of the hybrid to a patient as further described in the Examples herein.
- an irradiated semiallogeneic cell hybrid is provided.
- a method for making a cell hybrid of this invention includes the steps of a) contacting a cell deficient in ⁇ 2 microglobulin, having a selectable dominant marker and having a selectable recessive marker with a patient- derived tumor cell or white blood cell under conditions in which cell hybrids are formed; and b) selecting cell hybrids by determining the presence of the dominant marker and the presence of the recessive marker, whereby the presence of both the dominant and recessive markers is correlated with the presence of a cell hybrid.
- This method can further comprise the step of identifying cells that express HLA class I surface antigens. An example of this method is described in detail in the Examples section herein.
- a method of treating a cancer, HIV infection or other viral disease in a subject comprising administering to the subject an effective amount of a cell hybrid of the present invention, wherein patient-derived tumor cell or white blood cell is derived from the patient being treated, is provided.
- treating is meant an improvement in the patient's condition.
- the improvement can be in any of the parameters typically used by clinicians to assess the condition of the patient. For example, reduction in or stabilization of tumor mass or in antigen level in serum are evidence of efficacious treatment of a solid tumor. In the case of HIV infection or AIDS, reduction in HIV titre or increase in CD4 + counts in the peripheral blood are evidence of efficacious treatment of HIV infection or AIDS.
- a method of treating or preventing a solid tumor in a patient comprising administering to the patient an effective amount of a cell hybrid, wherein the patient- derived white blood cell is derived from the patient being treated and the fusion partner expresses a heterologous tumor antigen.
- the antigen expressed can be selected from the class of cancer-specific antigens, including, but not limited to those specifically named herein.
- a method of treating or preventing HIV infection or AIDS in a patient comprising administering to the patient a cell hybrid, wherein the patient-derived white blood cell is derived from the patient being treated and the fusion partner expresses a heterologous HIV-specific antigen.
- the antigen expressed can be selected from the class of HIV-specific antigens, including, but not limited to those specifically named herein.
- the present invention provides preventive and therapeutic vaccines for cancer or HIV infection, including AIDS, based on irradiated semi-allogeneic cell hybrids, generated by the fusion of patient-derived tumor or white blood cells, with the allo cell provided herein (26).
- Semi-allogeneic cell hybrids can be inactivated by irradiation and injected into the same patient to induce a specific anti-tumor or anti-HlN response, respectively.
- the present hybrids eliminate the need to establish patient-derived tumor cell cultures, which notoriously constitute a major technical hurdle.
- FO- 1 -derived HLA class I antigens may enhance the anti-tumor or anti-HIN response by virtue of the allogeneic presentation of tumor or HIN antigens; and cell hybrid vaccines exposed to a single lethal dose of ionizing radiation can express HLA class I surface antigens for several days before dying.
- the cancer or HIV infection or AIDS prevention or treatment method, wherein the cell hybrid is administered in conjunction with a cytokine is also provided.
- the cytokine can be interleukin-12 (IL-12), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), or a combination of these and other adjuvants.
- IL-12 interleukin-12
- GM-CSF granulocyte-macrophage colony-stimulating factor
- IL-2 interleukin-2
- Cell hybrids derived from the fusion of FO 1-12 cells with patient-derived melanoma cells or any other cell are selected by virtue of their HAT-resistant and neomycin-resistant phenotype as described below.
- the hybrids are thawed and used to prepare the irradiated vaccine for injection as described below.
- the vaccine consists of 5x 10 (or more) irradiated tumor cell hybrids.
- Irradiated cells are resuspended in 0.1 ml physiological saline and injected intradermally (i.d.) into the surface of the shoulder or other cutaneous area as deemed appropriate by the physician.
- Multiple vaccinations may be required to induce immunity.
- follow-up vaccinations can be made until complete remission or stabilization is achieved.
- a method of enhancing the proliferation and activation of a patient's cytotoxic T lymphocytes (CTL) specific for tumor-associated, HIV/AIDS-associated or autoimmune disease-associated antigen targets comprises contacting a population of peripheral blood mononuclear cells (PMBC), such as peripheral lymphocytes, from the patient with a cell hybrid of the present invention for an amount of time sufficient to increase the numbers and cytotoxic activity of CTL in the population.
- the amount of time can vary, but is expected to be in the range of from one to two weeks. An example of this method is provided in the Examples herein.
- contact includes close proximity as well as actual mechanical contact.
- the hybrids can be used in a method of treating a solid tumor in a patient.
- the method can comprise the steps of: a) obtaining a population of PBMC from the patient; b) contacting the population of PBMC with a cell hybrid of the invention for an amount of time sufficient to enhance the proliferation and activation of the patient's cytotoxic T lymphocytes; and c) returning the population of PBMC to the patient, whereby the tumor is treated.
- the step of obtaining a population of lymphocytes from a patient is accomplished by any of the well known methods of obtaining peripheral blood-derived lymphocytes. A specific example of one such method is described in the Examples. The length of contacting time is essentially as described below.
- the step of returning the activated lymphocyte population to the patient can be by known methods.
- the invention also provides a composition comprising a population of cytotoxic T lymphocytes produced by this method.
- This composition is a valuable reagent in the screening and identification of tumor-associated, HIV/AIDS-associated, or autoimmune disease-associated antigens or antigenic peptides.
- a method for educating patient-derived lymphocytes to enhance the activation of cytotoxic T lymphocytes specific for patient-derived tumor-associated, HIV/AIDS-associated, or autoimmune disease-associated antigens is provided.
- the patient-derived lymphocytes are educated by exposing them to irradiated semi- allogeneic cell hybrids derived from the fusion of patient-derived cells with a cell having a selectable dominant marker and having a selectable recessive marker (for example, the cell line FO-1 #12).
- the patient-derived cell used to form the semi- allogeneic cell hybrids can be a tumor cell or peripheral blood mononuclear cell (PBMC).
- PBMC peripheral blood mononuclear cell
- the patient-derived tumor cell can be a melanoma cell, a prostatic carcinoma cell, a colon carcinoma cell, a lung carcinoma cell, a breast carcinoma cell, a pancreatic carcinoma cell, a prostatic carcinoma cell etc.
- the patient-derived PBMC can be from patients with cancer, HIV-infection or AIDS, autoimmune disease, etc. An example of this method is described in the Examples.
- CTL can be obtained from the peripheral blood of any patient who responds clinically to any form of the present vaccine; in parallel, B lymphocytes from the same blood sample can be obtained and immortalized by infecting them with Epstein-Barr virus (EBV).
- EBV Epstein-Barr virus
- Patient-derived CTLs can be activated by exposing them to i ⁇ adiated, semi-allogeneic cell hybrids (vaccine) and tested for in vitro lysis of the patient's own B lymphocytes after they have been mixed with antigenic peptides extracted from the vaccine itself.
- Biological evidence of antigenic-mediated lysis can be used as a crucial indicator to pursue the identification by routine physical-chemical means (e.g., mass spectrometry) of the sequence of the antigenic peptides eliciting the cytotoxic response.
- routine physical-chemical means e.g., mass spectrometry
- cytotoxic T lymphocytes as cellular reagents in the identification of tumor-associated, HIV/AIDS-associated, and autoimmune disease-associated antigens or antigenic peptides is provided.
- FO-1 human cells are deficient in ⁇ 2 microglobulin production; therefore, they do not express HLA class I surface antigens (18). Expression of a transfected human ⁇ 2 microglobulin gene in FO-1 cells leads to restored expression of HLA class I antigens (19).
- FO-1 cells were mutagenized by exposing them to a single dose (3 Gy) of ⁇ - radiation (6 Gy/min dose rate) and subsequently plated in complete medium containing the purine analog 6-thioguanine at a concentration of 5 ⁇ g/ml.
- the incorporation into the DNA allows the selection of cells that are deficient for hypoxanthine-guanine phosphoribosyl transferase (hgprt).
- hgprt-deficient (hgprf) FO-1 mutants were isolated and characterized for their sensitivity to hypoxanthine, aminopterin, and thymidine (HAT)-containing medium.
- Neomycin-resistant clones were selected in Dulbecco's modified Eagle's medium (DMEM) with added 10% fetal bovine serum (FBS), 50 units/ml penicillin, 50 ⁇ g/ml streptomycin, and 40 ⁇ g/ml ciprofloxacin (complete medium), containing the neomycin analog geneticin (Gibco) at a concentration of 600 ⁇ g/ml. Neomycin-resistant clones became visible 3 weeks after transfection; and individual clones were expanded for further characterization. In another method of raising cells, the medium contained 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and no ciprofloxacin.
- this radiation dose was selected as a standard for inactivation of cells.
- FO-1 #12 a single clone (FO-1 #12) was selected for use in the subsequent experimentation, given the teaching of the present specification, it is expected that other cells having the key characteristics of the exemplary FO-1 #12 cells are within the scope of routine repetition of the above described steps.
- FO-1 #5 which has selectable dominant and recessive markers and is ⁇ 2 microglobulin deficient has also been made, and exhibits comparable biological properties.
- Polyethylene glycol(PEG)-mediated cell fusion (22) between neomycin- resistant, hgprf (HAT-sensitive) FO-1 #12 cells, and patient-derived cells was conducted according to the procedure by Prado et al (23).
- Prado et al 23
- the so-called stirring protocol is used (24).
- Neomycin-resistant and HAT-resistant melanoma cell hybrids (FO-1 #12 x 501) were subjected to immunofluorescent staining using anti-HLA-A,B,C + ⁇ 2 microglobulin mAb W6-32 and anti-HLA-A2 mAb PA2.1, followed by affinity-isolated fluorescein-labeled goat anti-mouse immunoglobulin (Fig.
- cell hybrids derived from the PEG-mediated fusion of FO-1 #12 cells with patient-derived tumor cells were generated and characterized. These patient- derived cells were obtained from tumor lesions removed as part of standard surgery and were in excess of the patients' needs. The resulting hybrids expressed HLA class I antigens.
- Tumor cell hybrids from over eighty independent experiments of PEG-mediated cell fusion have been obtained, including: two human melanoma cell lines; one human prostatic carcinoma cell line; over forty patient-derived primary melanoma cell suspensions; two patient-derived primary colon carcinoma cell suspensions; over twenty patient-derived lung carcinoma cell suspension; two white blood cell lines; and over ten HIV-infected patient-derived peripheral white blood cell suspensions.
- Semi-allogeneic cell hybrids tailored to and specific for each patient can be generated with cell suspensions from any solid tumor or from white blood cells; they can be propagated and irradiated before injecting them into each patient for the purpose of therapeutic as well as preventive vaccination.
- irradiated tumor cell hybrid vaccines can be formulated with appropriate cytokines (IL-12, GM-CSF, IL-2, etc.) for enhanced efficacy.
- Peripheral mononuclear lymphocytes are obtained from 20 ml of heparinized human blood. After diluting blood with Hank's balanced salt solution (HBSS) at a 1:1 ratio, the suspension is layered over the separation medium (Lymphocyte Separation Medium- LMS- Organon Teknika) and spun down at 400xg at room temperature for 15-30 min. Centrifugation sediments erythrocytes and polynuclear leukocytes and bands mononuclear cells which can be aspirated, transferred to a centrifuge tube and diluted with an equal volume of HBSS.
- HBSS Hank's balanced salt solution
- the mononuclear lymphocyte suspension is spun down for 10 min at room temperature at a speed sufficient to sediment the cells without damage (i.e., 160-260xg). Cells are washed again in HBSS, resuspended in appropriate diluent and counted before using them for fusion. Derivation of tumor cell suspensions from surgically excised lesions:
- the present protocol is a modification of the tumor disaggregation protocol by Yannelli et al (25). Tumors are retrieved immediately after excision from each patient, put in Hank's balanced salt solution (HBSS) on ice, and transported to the laboratory. Tumor specimens are then transferred under sterile conditions to a 100 mm culture dish containing HBSS. After separating fat and necrotic tissue away from tumor tissue (1-2 grams), the latter is minced into pieces as small as possible using scalpel blades.
- HBSS Hank's balanced salt solution
- Minced tumor tissue fragments are transferred to flasks containing 25-50 ml of an enzymatic solution made of RPMI medium without serum, containing type I collagenase (1.0 mg/ml, Worthington) and DNase I (0.1 mg/ml, Sigma).
- the flask containing tumor cells is incubated at room temperature for 16-18 hours on a magnetic stir plate.
- the digested tumor cell suspension is then filtered through a sterile Nitex 40 nylon filter (mesh size 95 ⁇ m) to exclude undigested tumor fragments.
- the cell suspension is transferred to 50 ml conical centrifuge tubes and spun at 250xg for 10 min at 4°C in a refrigerated centrifuge, washed once with HBSS, resuspended in an appropriate volume of HBSS and layered over Lymphocyte Separation Medium (LMS, Organon Teknika) and spun down at 400xg at room temperature for 15-30 min. Centrifugation sediments erythrocytes and polynuclear leukocytes and bands mononuclear blood cells and tumor cells which can be aspirated, transferred to a centrifuge tube and diluted with an equal volume of HBSS.
- LMS Lymphocyte Separation Medium
- the cell suspension is spun down for 10 min at room temperature at a speed sufficient to sediment the cells without damage (i.e., 160-260xg). Cells are washed again in HBSS, resuspended in appropriate diluent and counted and checked for viability by trypan blue exclusion test. Separate aliquots of the single cell suspension are used for a) fusion with FO-1 #12 cells to derive tumor cell hybrids, b) growth of tumor-infiltrating lymphocytes, and c) freezing for later use as autologous targets in cytotoxicity assays (see below). During processing, all solutions include gentamicin (50 ⁇ g/ml). Formation, propagation, and i ⁇ adiation of tumor cell hybrids:
- Single-cell suspensions of patient-derived tumor cells (lxl 0 7 cells/ 100 mm dish) are plated on tissue culture dishes in DMEM supplemented with 10% FBS, streptomycin (100 ⁇ g/ml) and gentamicin (10 ⁇ g/ml). The following day, 4xl0 6 FO-1 #12 cells are added to each dish of patient-derived cells for co-cultivation. After 4-5 hours of co-cultivation, cells are rinsed twice with serum- free DMEM prewarmed at 37° (D37°), and exposed for 5 min to 50 ⁇ M sodium dodecylsulfate (SDS) in D37°.
- SDS sodium dodecylsulfate
- SDS -containing medium is suctioned off and the monolayer is treated with 3 ml/dish of 50% PEG in D37° for fusion.
- the PEG solution is suctioned off and the monolayer rinsed three times with D37° before adding complete medium containing 15 ⁇ g/ml hypoxanthine, 0.2 ⁇ g/ml aminopterin, 5 ⁇ g/ml thymidine (HAT).
- HAT ⁇ g/ml hypoxanthine
- 0.2 ⁇ g/ml aminopterin 5 ⁇ g/ml thymidine
- PBMC peripheral blood mononuclear cells
- a modification of the stirring protocol is used (24).
- PBMC and FO-1 #12 cells are washed by centrifugation in D37° and then mixed at an approximate 5:1 ratio (25 million PML:5 million FO-1 #12 cells).
- the resulting cell mixture is then spun at 300xg for 5 min in D37° containing 50 ⁇ M SDS.
- the mixed cell pellet is resuspended in 1 ml 50% PEG added slowly over 1 minute, and then stirred for an additional minute.
- 10 mis D37° is slowly added over 2 minutes while stirring.
- the cell suspension is then centrifuged at 300xg for 5 min.
- the cell pellet is resuspended in complete medium containing 15 ⁇ g/ml hypoxanthine, 0.2 ⁇ g/ml aminopterin, 5 ⁇ g/ml thymidine (HAT).
- HAT thymidine
- Cell hybrids derived from the fusion of FO-1 #12 cells with patient-derived PML are selected by virtue of their HAT- resistant and neomycin-resistant phenotype and are propagated in selective medium for several weeks.
- Cell hybrids derived from the fusion of FO 1-12 cells with patient-derived melanoma cells are selected by virtue of their HAT-resistant and neomycin-resistant phenotype and propagated in selective medium for several weeks.
- the HAT-resistant and neomycin-resistant cell population is then subjected to immuno fluorescent staining using anti-HLA class I antigen mAb W6-32, followed by affinity-isolated fluorescein-labeled goat anti-mouse immunoglobulin.
- Mab W6-32 (corresponding hybridoma obtained through ATCC) is available as sterile ascites obtained from virus-free, immunodeficient (nude) mice and is used as a 1 : 1000 dilution in staining solution (full reactivity of W6-32 sterile ascites at 1 :4000 dilution was documented).
- the surface expression by HAT-resistant and neomycin-resistant cells of HLA class I antigens confirms the presence of true hybrids.
- tissue typing of patient-derived white blood cells and tumor cell hybrids is performed.
- mycoplasma and endotoxin testing are initiated on the fin cell hybrid preparation for injection and on the autologous tumor cells and peripheral blood leukocytes used for skin tests. A gram stain is performed on the hybrid cells prior to injection.
- Mycoplasma testing can be performed utilizing the PCR-based detection kit manufactured by Stratagene (catalog #302007), which allows the identification of any of five strains of mycoplasma commonly associated with cell culture infections.
- Endotoxin testing can be performed using the Limulus Amebocyte Lysate-based kit (Pyrogent Plus Gel-Clot LAL) manufactured by Bio-Whittaker (Walkersville, MD). Preparation of irradiated hybrids for vaccination:
- Neomycin-resistant, HLA class I antigen-expressing hybrids are expanded and frozen down in aliquots of 6x10 or more cells.
- Samples of cell hybrids from each patient can be identified by some accepted identifier (e.g., the patient's initials followed by their hospital registration number and the letters FO-1).
- TIL tumor-infiltrating lymphocytes
- PBL peripheral blood lymphocytes
- TIL cultures are established as described by Yannelli et al. (25).
- Initial single- cell suspensions containing tumor cells, lymphocytes, macrophages, and stromal cells (5xl0 5 cells/ml), are seeded in 24-well culture plates (2 ml/well) in RPMI (Gibco-BRL) supplemented with 10% human AB serum, streptomycin (100 ⁇ g/ml), gentamicin (10 ⁇ g/ml), 2 mM L-glutamine, and interleukin-2 (IL-2, Cetus-Chiron, 6000 IU/ml).
- RPMI Gibco-BRL
- gentamicin 10 ⁇ g/ml
- 2 mM L-glutamine interleukin-2
- IL-2 interleukin-2
- TIL T cell markers
- PBL peripheral blood-derived lymphocytes
- mononuclear cells are obtained from heparinized blood as described above and grown in AIM-V (Gibco- BRL) supplemented with 10% human AB serum, streptomycin (100 ⁇ g/ml), gentamicin (10 ⁇ g/ml), 2 mM L-glutamine, and interleukin-2 (IL-2, Cetus-Chiron, 6000 IU/ml) for 1-2 weeks.
- the cells can then be tested for the expression of T cell markers (MHC class II, CD3, CD4, CD8) by flow cytometry using commercially available reagents (Coulter) before using the cells in experiments of "education" with semi-allogeneic cell hybrids.
- target cells can be patient-derived tumor cell suspensions, patient-derived peripheral blood mononuclear cells (for example, in patients with HIV/ AIDS or autoimmune disease), Epstein-Ban virus (EBV)- transformed B lymphocytes loaded with appropriate antigenic peptides (26), or other HLA-matched antigen-presenting cells, such as T2 cells.
- patient-derived tumor cell suspensions for example, in patients with HIV/ AIDS or autoimmune disease
- patient-derived peripheral blood mononuclear cells for example, in patients with HIV/ AIDS or autoimmune disease
- EBV Epstein-Ban virus
- T2 cells such as T2 cells.
- Ex experimental release of 51 Cr (cpm/min)
- S spontaneous release of chromium-51 (cpm/min) by target cells
- M maximum release of 51 Cr (cpm/min) by target cells when lysed by 0.1 N hydrochloric acid.
- 5 'Cr-labeled Daudi cells were used as targets for lymphokine-activated killer (LAK) cell activity and 51 Cr-labeled K562 cells as targets for natural killer (NK) cell activity, in order to ascertain that any change in cytotoxicity after exposure of lymphocytes to inadiated hybrids was T cell-mediated rather than being the result of increased LAK or NK cell activity (LAK and NK cell activities are not HLA- restricted).
- the results of cytotoxicity experiments are shown in Tables 1 and 2. Values representing percent lysis are conected for the percent lysis by each effector of 51 Cr-labeled Daudi cells used as a non-specific target.
- Table 1 shows percent of TIL-mediated lysis of autologous melanoma cells (target) from patient JPl. Values shown were conected for the % lysis by each effector of Daudi cells used as a target for lymphokine-activated killer (LAK) cells. a ND: not determined (JPl -TIL were growing poorly in the absence of stimulation with inadiated hybrids).
- Table 2 shows the percent of TIL-mediated lysis of autologous melanoma cells (target) from patient GTl .
- a control was performed with GTl-TIL exposed to inadiated FO-1 parental cells transfected with the ⁇ 2 microglobulin gene. These FOl- ⁇ cells express allogeneic MHC class I molecules on the cell surface.
- This experiment demonstrates that allogeneic stimulation per se does not enhance specific cytolytic activity by the TIL as does the semi-allogeneic stimulation by the GTlxFOl hybrids. Values shown were conected for the % lysis by each effector of Daudi cells used as a target for LAK cells.
- HIV + (HIV-positive) patients were enrolled in a joint study of a Department of Radiation Oncology, and the Division of Infectious Disease, Medical University of South Carolina, Washington, SC, USA. Whole blood was collected at three monthly intervals and shipped overnight to the NCI for in vitro experiments. The study was reviewed and approved by Institutional Review Boards from both Institutions. Most HIV + patients tested had low detectable viral loads ( ⁇ 400 copies/ml) and CD4 + counts above 250 cells/ml. The information on viral loads, CD4 + and CD8 + counts, and antiretroviral therapy from the six patients who were tested for CTL are presented in Table 3.
- Antiretroviral therapy included: AZT, 3TC (Lamivudine), IND (Indinavir), and ddL (Didanosine) and Nelfinavir.
- PEG-mediated fusion was performed according to a modification of the procedure described by Galfre (24).
- PEG-1450 was used as a fusion agent (Sigma, St. Louis, MO). Briefly, PBMC from donors (2.5 X 10 7 cells/ml) and the allogeneic melanoma line FOl-12 (5 X 10 6 cells/ml) were washed and centrifuged at 1000 m in DMEM without serum. The cell pellet was resuspended in medium without serum containing 50 ⁇ M SDS (Sigma), and PBMC were mixed with FOl-12 line at 5:1 ratio and spun at 1200 ⁇ m. The mixed cell pellet was slowly resuspended in 1 ml 55% PEG for 1 minute.
- HAT HAT-resistant and neomycin-resistant hybrids were tested for surface expression of HLA class I antigens by immuno fluorescence using monoclonal antibodies to Human class I antigens (Pharmingen, San Diego, CA). Tissue typing of donor PBMC and hybrids was performed by molecular typing using PCR technique in the NIH HLA Laboratory (Bethesda, MD).
- cytokines by semi-allogeneic hybrids or FOl-12 line was assessed by culturing 1.5 X 10 6 cells/ml in DMEM medium with 10% FBS in 24-well plates in a humidified, 37°C, 5% CO 2 incubator. Cells were unstimulated and were either uninadiated or inadiated (25 Gy). Culture supernatants were harvested after 24 and 48 hr and stored at -80°C. Total IL-12 p40, IL-2, IL-4, IL-6 production were determined by ELISA (Genzyme, Cambridge, MA). IL-10, IL-5, IFN- ⁇ , and TNF- ⁇ production were assessed using Pharmingen capture and detection antibodies (Pharmingen). The IL-12 p70 heterodimer production and GM-CSF release were assessed by ELISA ( R&D, Minneapolis, MN).
- Hybrids and FOl-12 cells were washed three times with staining buffer (PBS plus 0.1% BSA). Approximately 10 6 cells were incubated with human IgG (20 ⁇ g/ml) for 10 minutes at 4°C to block Fc receptors, and than stained with FITC or PE conjugated mAb W6-32 (anti-HLA- A,B,C+ ⁇ 2 -microglobulin), anti-CD80 (B7.1), anti- CD86 (B7.2), anti-HLA DR, anti-HLA DQ (Becton Dickinson, Mountain View, CA) or with isotype-matched Ab for 30 minutes at 4°C. Cells were washed twice and resuspended in staining buffer and surface molecule expression was determined by FACS analysis using a FACScan (Becton Dickinson) and CellQuest software.
- HIV-1 envelope peptides used in this study were synthesized as previously described (36-38), and are identical to those previously reported in HIV + patients studies by our laboratories (39, 40).
- the peptides based on sequence of gpl60 HIV-1 IIIB are: env Tl (aa residues 428-443 :gp 120); env T2 (aa residues 112-124: gpl20): e ⁇ Th4.1 (aa residues 834-848: gpl60) and e «v P18 (aa residues 315-329: gpl ⁇ O).
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- donor PBMC were stimulated with either inadiated (25 Gy) allogeneic cells or semi-allogeneic hybrid cells (at responder: stimulator ratio 3:1) or env peptide pool (5 ⁇ M of each peptide) for 6 days as previously described (18, 33).
- PBMC culture at 5 ⁇ M concentration for each peptide during the six day stimulation of CTL.
- PBMC peripheral blood mononuclear cell
- inadiated semi-allogeneic hybrids were pulsed with env peptides for 1 hr at 37°C, washed and then mixed with PBMC. Both 1) and 2) above were cultured for six days to generate ewv-specific CTL.
- Target cells were EBV-transformed B lymphoblastoid cell lines. Autologous EBV lines were generated incubating PBMC with the supernatant of B95.8 cells, a cell line that chronically produces Epstein Ban virus, and an anti-CD3 monoclonal antibody (Pharmingen). Target cells were pulsed overnight with either env peptide pool (5 ⁇ M each) or no peptides. After three washes the targets were labeled with Chromium-51 (150 ⁇ Ci ⁇ a ⁇ 'CrO ⁇ Amersham, Piscataway, ⁇ J) for 2 hr at 37°C.
- Chromium-51 150 ⁇ Ci ⁇ a ⁇ 'CrO ⁇ Amersham, Piscataway, ⁇ J
- the targets were resuspended at a 5 X 10 3 cells/well in RPMI 1640 containing 5% human AB + serum and incubated in 96- well round bottom microtiter plates in triplicates at effector: target ratio 30: 1, 10:1, 3:1, and 1 : 1.
- Spontaneous release was determined in targets cultured in medium alone. Maximal release was determined from targets cultured with 5% Triton X-100. After 6 hr of incubation, supernatants were harvested and counted in a ⁇ counter. Percent specific lysis was determined as 100% X (experimental cpm- spontaneous cpm)/(maximum cpm-spontaneous cpm).
- ETL cells cytotoxic T lymphocytes (CTL) that lyse (kill) target cells. Effector cells are generated from cytotoxic precursor cells by stimulator cells that can be peptide-loaded autologous cells or in this invention also peptide-loaded hybrid cells. "Peptide-loaded” is the same as “peptide-pulsed.”
- FOl-12 cells which express class II HLA antigens, were used as an allogeneic donor cell line for preparing semi-allogeneic cell hybrids with uninfected donor (HIV ) or HIV + patient-derived cells.
- HIV uninfected donor
- HAT- sensitivity hgprt "
- FOl-12 cells are also deficient in ⁇ 2 -microglobulin production, because of the deletion in the conesponding gene, and do not express HLA class I surface antigens (18).
- expression of class I on the hybrid cells provides additional evidence of fusion and verifies co-expression of patients' self-MHC class I.
- Hybrid cells generated by fusion with FOl-12 express HLA class I surface antigens derived from both FOl-12 and the patient, due to the expression of the patient-derived ⁇ 2 -microglobulin gene.
- the neomycin-resistant/HAT-resistant cell hybrids were tested for HLA class I expression by immunostaining and flow cytometry.
- the percentage of HLA class I-expressing cell hybrids was greater than 90%, and the hybrids were stable in culture over time in terms of the percentage class I- expressing cells. These three markers greatly simplify the screening of semiallogeneic cell hybrids, and were used to confirm hybrid formation.
- the hybrid cell lines were subjected to molecular HLA haplotype analysis by the NIH HLA Laboratory, including molecular typing of FOl-12 cells expressing the ⁇ 2 -microglobulin gene (FOl- ⁇ 2 ) (19) (Table 4).
- PBMC from the patients were also analyzed for HLA class I expression. All of the hybrids tested expressed HLA class I and II antigens derived from both fusion partners.
- Table 4 HLA class I and II antigen expression by FOl-12 line; FOl- ⁇ 2 line expressing a transfected ⁇ 2 -microglobulin gene (19); PBMC and hybrid cell lines from six HIV + patients analyzed for CTL activity.
- Hybrid-3 A30,A32,B8 0301,01 02, 0501 3*0101, 3*02
- Hybrid-4 A25, A68, B8 0301, 15 02, 06 3*0101, 5*01
- PBMC-5 A32, A33, 12, 1304 0301, 0501 3*0101, 3*02 B5801,
- Antiretroviral therapy included: AZT, 3TC (Lamivudine), IND (Indinavir), and ddL (Didanosine) and Nelfinavir.
- cytokine gene-transduced tumor cells can exhibit elevated cytokine production after inadiation (41 , 42), we compared cytokine production before inadiation and 24 and 48 hr post irradiation.
- An increase in interleukin-2 (IL-2) production (4- to -8-fold) was observed in all hybrids tested 24 hr (Fig. 5A) and 48 hr post inadiation.
- mitomycin C Sigma, 200 ⁇ g/ml for 2 hr at 37°C
- no IL-2 release was detected (Fig. 5 A).
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- the PBMC were stimulated with env pool alone or with semiallogeneic hybrids alone to obtain control values.
- PBMC cultures were assayed six days later for cytotoxic activity against EBV- transformed autologous B lymphoblastoid cell lines pulsed with the env peptide pool or with media (specificity control) in a 6-hr 51 Cr-release assay.
- PBMC from three of the six HIV + donors tested generated cytolytic activity against peptide-pulsed targets (Fig.
- the alloantigens (hybrid) and env plus self-MHC (self- APC in the PBMC) are presented on separate APC (illustrated in Fig. 8A).
- the inadiated hybrid cells were similarly pulsed with env peptides and washed prior to adding PBMC.
- the alloantigens and env plus self-MHC are expressed on the same APC (hybrid) (illustrated in Figure 8 B).
- the two e «v-specific CTL responses generated were equivalent, and were indistinguishable from the CTL response generated by PBMC plus hybrid cells that were incubated with env peptides for the six days (Fig. 7).
- Control groups for absence of semi-allogeneic hybrids include PBMC stimulated only with env for 6 days, and PBMC pulsed with env and washed prior to 6 day culture.
- the e «v-specific T cell activity was 5 -to- 10-fold lower in PBMC stimulated with env only than with env plus hybrid cells (Fig. 7).
- the control group stimulated with hybrid alone was 30-fold below the other groups, confirming that semi-allogeneic stimulation alone did not result in the activation of e «v-specific CTL activity.
- hybrid cell lines formed by the fusion of the FOl-12 melanoma line with HIV + patients' PBMC express class I and II MHC antigens of both fusion partners, and also express at least one of the costimulatory molecules (CD86) necessary for providing the second signal in T cell activation.
- CD86 costimulatory molecules
- These hybrid lines can also stimulate T cell proliferation and can present env peptides to patients' CTL precursors and provide alloantigen-driven costimulation, resulting in the generation of env-specific CTL.
- the fact that we can increase env-specific CTL activity may be important, as it is considered that the Th response to HIV antigens is possibly the first response to be lost after HIV infection (43).
- the present study is also the first to demonstrate the costimulatory effect in which human allogeneic and self-HLA determinants are both expressed on the same APC resulting in HIV-specific CTL activity.
- HLA class I provided convenient immunologic evidence of successful fusion.
- Our findings that the semi-allogeneic hybrids expressed HLA class I and II antigens derived from both cells of origin and also expressed CD86 suggests that the semi-allogeneic hybrids can serve as APC and provide costimulatory signals.
- the expression of co-stimulatory molecules may be important, because macrophages derived from PBMC of AIDS patients are deficient in CD80/86 expression (45).
- costimulation of T cells from HIV + patients with haplo- mismatched hybrids can increase env-peptide-specific CTL activity relative to the CTL activity generated by env peptides without alloantigen costimulation.
- No additional enhancement was demonstrated in vitro by having the allogeneic (helper) and self- restricting (effector) HLA antigens expressed on the same APC, compared to the expression of allogeneic and self MHC antigens on separate APC in the same well.
- This study demonstrates that hybrid cell lines formed between the patient's PBMC and a genetically-engineered human melanoma cell line can present peptide antigens that stimulate HIV env-specific CTL.
- OBJECTIVES The primary objectives of this clinical study are to determine whether treatment with irradiated, semi-allogeneic cell hybrids mixed with HIV-derived peptides is associated: a) with restoration or improvement of delayed-type hypersensitivity (DTH) response to certain recall antigens (mumps and Candida) and to allo stimulation (the patient's own semi-allogeneic hybrids); and b) with the ability of PBMC to specifically lyse immortalized B lymphocytes (from the same patient) expressing HIV-derived antigenic peptides.
- DTH delayed-type hypersensitivity
- mumps and Candida recall antigens
- allo stimulation the patient's own semi-allogeneic hybrids
- PBMC to specifically lyse immortalized B lymphocytes (from the same patient) expressing HIV-derived antigenic peptides.
- Secondary objectives of this clinical study are: a) to monitor the patient's profile of CD4 counts and viral load for the duration of the clinical study; b) to identify patients who express HLA- A2 antigen in order to test their peripheral mononuclear cells (PBMC) for the ability to recognize specific, HLA- A2 -restricted epitopes derived from influenza A virus and HIV-1; and c) to measure the release of soluble factors with anti-HIV activity by patient-derived PBMC when exposed to semi-allogeneic hybrids.
- PBMC peripheral mononuclear cells
- FOl-12 cells (35), which express HLA class II antigens, were used as an allogeneic donor cell line for preparing semi-allogeneic cell hybrids with patient- derived cells.
- a dominant selectable marker neomycin-resistance
- HAT-sensitivity hgprt "
- FOl-12 cells are also deficient in ⁇ 2 -microglobulin production because of a deletion in the conesponding gene, and they do not express HLA class I antigens on the cell surface (18).
- expression of class I on the hybrid cells provides additional evidence of fusion, due to the presence of the patient-derived ⁇ 2 -microglobulin gene.
- the neomycin- and HAT-resistant cell hybrids were tested for HLA class I expression by immunostaining and flow cytometry. The percentage of HLA class I-expressing cell hybrids was greater than 90%, and this percentage was stable in culture over time. Together, these three markers greatly simplify the selection and screening of semiallogeneic cell hybrids.
- FOl-12 cells were certified for human use, and a Master Cell Bank (manufactured for us by Magenta Co ⁇ oration/Microbiological Associates, Rockville, MD) was utilized for the generation of semi-allogeneic cell hybrids for subsequent clinical studies (see below).
- Semi-allogeneic hybrids express the class I antigens of both patient and FOl-12 cells, as demonstrated by serological HLA haplotyping (Table 6).
- HLA class I haplotypes expressed by semi-allogeneic tumor cell hybrids HLA class I tissue-typing was performed using FO-1 cells expressing a transfected ⁇ 2 - microglobulin gene (FOl-12 haplotype) (19); patient-derived tumor-infiltrating lymphocytes (patient haplotype); and hybrids resulting from the fusion of FOl-12 cells with patient-derived tumor cells (hybrid haplotype).
- FOl-12 haplotype transfected ⁇ 2 - microglobulin gene
- patient haplotype patient-derived tumor-infiltrating lymphocytes
- hybrids resulting from the fusion of FOl-12 cells with patient-derived tumor cells hybrids resulting from the fusion of FOl-12 cells with patient-derived tumor cells.
- the patient samples shown represent three melanomas and two lung adenocarcinomas.
- Cytotoxic T cell responses were evaluated in six HIV + donors (58).
- each patient's PBMC were stimulated with an HIN-1 env peptide pool alone or the pool plus semiallogeneic hybrids derived from that patient.
- PBMC were stimulated with env pool alone or with semi-allogeneic hybrids alone.
- PBMC cultures were assayed six days later for cytotoxic activity against EBN-transformed autologous B lymphoblastoid cell lines pulsed with the env peptide pool or with media in a 6-hr 51 Cr- release assay.
- PBMC from three of the six HIV + donors tested exhibited cytolytic activity against peptide-pulsed targets [Fig.
- Patient#l (Fig. 9, panel B) is an example of the three patients whose PBMC did not generate HIV-specific CTL even when stimulated with env peptides plus semi-allogeneic hybrids.
- PBMC Human-derived PBMC are obtained from approximately 25 ml of heparinized whole blood. Blood is diluted with Hanks' balanced salt solution (HBSS), layered over lymphocyte separation medium (LSM, Organon Teknika), and centrifuged at 400 g for 15-30 min. Centrifugation through this ficoll gradient sediments erythrocytes and polynuclear leukocytes, while an interface band of mononuclear cells can be removed, washed twice with HBSS, resuspended in Dulbecco's modified Eagle medium
- DMEM fetal calf serum
- PBMC and FOl-12 cells obtained from the certified Master Cell Bank
- serum-free DMEM obtained from the certified Master Cell Bank
- serum-free DMEM obtained from the certified Master Cell Bank
- the cell mixture id then centrifuged at 250g and resuspended in 1 ml 50% PEG in serum-free DMEM (added slowly with constant stirring over a 1 minute period).
- HAT-resistant and neomycin-resistant cell population is tested for the surface expression of HLA class I antigens by immunofluorescent staining using anti-HLA class I mAb W6-32, followed by fluorescein-labeled secondary antibody.
- the surface expression by HAT-resistant and neomycin-resistant cells of HLA class I antigens confirms that we have obtained true hybrids.
- Cell hybrids can easily be propagated to expand their numbers to cryopreserve several aliquots of -1.0x10 7 (or more) cell hybrids in a solution of 90% FBS/10% DMSO. Samples of cell hybrids from each patient are identified by the patient's initials followed by a numerical digit and the suffix "x FO1."
- B cell lines About 5 ml of heparinized blood is used to produce immortalized B cell lines from each patient by incubating PBMC with the supernatant of B95.8 cells (a cell line that chronically produces Epstein-Ban virus) and an anti-CD3 monoclonal antibody (Pharmingen, CA).
- B95.8 cells a cell line that chronically produces Epstein-Ban virus
- an anti-CD3 monoclonal antibody Pharmingen, CA.
- the B cell lines can then be cryopreserved in 90% FBS/10% DMSO until needed as targets in cytotoxicity experiments designed to test the ability of patient-derived PBMC to recognize HIV-derived antigenic peptides before and after treatment.
- Inclusion Criteria The following is an example of criteria that may be used to determine whether a patient can be treated with this protocol.
- Exclusion Criteria The following is an example of criteria that may be used to determine whether a patient should not be treated with this protocol.
- cytokines with the exception of erythropoietin and recombinant human growth hormone
- systemic corticosteroids hydroxyurea
- immunomodulatory therapy cytotoxic agents, or antimetabolites
- c. comprehensive metabolic panel including as a minimum: electrolytes, creatinine, blood urea nitrogen, glucose, TSH, aspartate amino transferase (AST/SGOT), alanine amino transferase (ALT/SGPT), total bilirubin, creatinine kinase (CK), LDH, calcium, phosphorus, magnesium, and albumen
- mumps and Candida recall antigens
- 2x10 6 autologous inadiated PBMC negative control
- 2xl0 6 inadiated semi-allogeneic hybrids allo
- a cryogenic vial containing patient-specific, semi- allogeneic hybrids is thawed to prepare the cells for injection.
- the cells are gently thawed in 1 ml FBS, washed three times in HBSS, counted, and tested for viability by trypan blue exclusion (not less than 70% viability will be acceptable).
- 1.0-3.0xl0 7 cell hybrids (depending on appropriate dose) are resuspended in 0.1 ml/1.0x10 7 cells of injectable saline containing a mixture of HIV-derived peptides and loaded in a 1-ml tuberculin syringe. The resulting suspension is exposed to a single lethal dose of 25 Gy ⁇ -rays. Excess numbers of cell hybrids are used in microbiology testing as described below.
- Sterility and mycoplasma testing is performed on the final cell hybrid preparation for injection. Specifically, gram stain and microbiology culture are performed by the clinical laboratories. Mycoplasma testing is performed utilizing the PCR-based detection kit manufactured by Stratagene, which allows the identification of any of five species of mycoplasma commonly associated with cell culture infections. Endotoxin testing is performed on the supernatant from the final cell wash using the Limulus Amebocyte Lysate-based kit (Pyrogent Plus Gel-Clot LAL) manufactured by Bio-Whittaker (Walkersville, MD).
- the inadiated cell/peptide mixture is administered by intradermal injection at the upper arm and thigh (alternating sides) or as deemed appropriate by the physician.
- DTH results are scored by an independent physician 48 hours after skin test placement.
- Patients are enrolled in the study and treated in cohorts of five patients per dose level.
- the initial dose is lxlO 7 cell hybrids per injection and is escalated by lxlO 7 cells per dose up to a maximum of 3x10 7 cells per injection, which implies the enrollment of fifteen patients divided into three cohorts of five patients each per study site (MUSC and NIH). Therefore, approximately thirty patients are in this study.
- Immortalized B lymphocytes (derived from each patient) expressing HIV- derived antigenic peptides are used as targets in cytotoxicity experiments designed to determine the ability of patient-derived PBMC to recognize HIV-infected cells.
- cytotoxicity experiments designed to determine the ability of patient-derived PBMC to recognize HIV-infected cells.
- -30 ml of heparinized whole blood are drawn, and PBMC are obtained by centrifugation through a ficoll gradient (lymphocyte separation medium) as described above.
- 3xl0 6 PBMC are incubated for 6 days with lxl 0 6 inadiated (25 Gy) semiallogeneic hybrids and HIV-derived peptide pool (2.5 ⁇ :M) at 37° C in a humidified 5% CO 2 incubator in RPMI 1640 medium supplemented with 5% human AB + serum.
- the cells are washed and resuspended in RPMI 1640 medium with 10% FBS and used as effectors in a CTL assay.
- EBV-immortalized B cells expressing HIV-derived antigenic peptides (target cells) are labeled with 51 Cr isotope and pulsed overnight with either HIV peptide pool (5 ⁇ :M) or no peptides.
- Additional targets are immortalized B cells infected with influenza virus. After three washes, the targets are resuspended at 5xl0 3 cells/well in RPMI 1640 containing 10% FBS and incubated in a 96-well round bottom microtiter plate in triplicate. Stimulated PBMC effector cells are added at Effecto ⁇ Target ratios 20:1, 10:1, and 5:1. Spontaneous release is determined in target cells cultured in medium alone, and maximum release is determined from targets cultured with 5% Triton X-100. After six hours' exposure, supernatants are analyzed for 51 Cr release in a gamma counter. Percent specific lysis is determined as 100 X (experimental cpm - spontaneous cpm)/(maximum cpm -spontaneous cpm).
- PBMC are obtained by centrifugation through a ficoll gradient (lymphocyte separation medium) as described above.
- T2 and Daudi cells load with 51 Cr isotope alone will be used as control targets for non-specific lysis.
- PBMC effectors and 51 Cr-loaded target cells will be mixed at 1 : 1 , 5 : 1 , and 15:1 ratios in 96- well plates, and incubated at 37°C in Iscove's complete medium.
- Spontaneous release is determined in target cells cultured in medium alone, and maximum release is determined from targets cultured with 5% Triton X-100. After four hours exposure, supernatants will be analyzed for 51 Cr release in a gamma counter. Percent specific lysis is determined as 100 X (experimental cpm - spontaneous cpm)/(maximum cpm - spontaneous cpm). Measurement of soluble factors with anti-HIV activity
- Biological response will be determined by comparing DTH response to recall antigens (mumps and Candida) and to allo stimulation (the patient's own semiallogeneic hybrids) between time of enrollment (time of 1st injection) and time of evaluation (1 and 4 weeks after the 4th injection). DTH response will be read 48 hours after skin test placement and will be measured as the product of two pe ⁇ endicular diameters (in millimeters) of any induration/erythema exhibited by the patient at each injection site. A positive response will be defined as a restoration or improvement in DTH response to recall antigens and allo stimulation before and after treatment.
- PBMCs are added to PHA-stimulated PBMCs during the in vitro infection of these PHA-stimulated cells with HIV. This procedure is performed to determine whether the 7-day, hybrid-stimulated culture supernatants contain anti-viral activity that inhibits in vitro HIV replication as previously reported (54, 55).
- Biological response will also be determined by comparing cytotoxic activity of patient-derived PBMC cells expressing HIV-derived antigenic epitopes, between time of enrollment and time of evaluation (as defined above).
- a positive response will be defined as the measurable acquisition or improvement in the cytotoxic activity of patient-derived PBMC toward immortalized B lymphocytes (from the same patient) expressing HIV-derived antigenic peptides.
- CD4 counts and viral load will be monitored throughout the duration of the study. Also, two days before the 1st injection, and one and four weeks after the 4th injection, patient-derived PBMC will be tested for the ability to generate soluble factors with anti-HIV activity when exposed to semi-allogeneic cell hybrids and the HIV-specific peptide pool.
- HLA-A2+ two days before the 1st injection, and one and four weeks after the 4th injection, their PBMC will also be tested for the ability to recognize specific, HLA-A2 -restricted Flu-Mi and HIVgag-derived peptides.
- a positive response will be defined as the measurable acquisition or improvement in the cytotoxic activity of patient-derived PBMC (after treatment) toward target cells loaded with FLU-MI and HIVgag-derived peptide.
- DTH delayed-type hypersensitivity
- HLA-A2 HLA class I
- DR class II
- PBMC peripheral blood mononuclear cells
- Iscove's medium supplemented with 10% human AB serum and interleukin-2 (IL-2, Proleukin, Cetus- Chiron, 300 IU/ml), since lymphocytes cannot be maintained in culture at sufficient numbers without this cytokine.
- IL-2 interleukin-2
- PBMC peripheral blood mononuclear cells
- FLU-MI 58 . 66 GILGFVFTL 1 ⁇ g/ml HLA-A2- restricted FLU-MI peptide
- no antigen as a negative control.
- PBMC underwent two cycles of antigenic stimulation for a total of 14 days.
- PBMC-derived effector cells were then harvested and used in cytotoxicity experiments.
- Target cells for these assays were T2 cells (66); these cells are commonly used as targets for cytotoxicity experiments because they express empty HLA-A2 class I molecules on their surface and can be easily loaded with exogenous antigenic peptides.
- T2 cells were loaded with radioactive 51 Cr and 5 ⁇ g/ml FLU-MI peptide. Unloaded T2 cells (no peptide) and Daudi cells were used as control targets for non-specific, lymphokine-activated killing. Lysis was performed for four hours with effector :target ratios of 1:1 and 5:1, and the release of radioactivity was measured in a gamma counter. The results of these studies are shown in Table 7.
- Cytotoxicity assay showing % lysis ( 51 Cr-release) values of T2 target cells that have been loaded with exogenous FLU-MI peptide (or unloaded control).
- Effector cells are PBMC from a healthy HLA-A2 + volunteer that have been exposed to the same peptide with or without inadiated, semi-allogeneic hybrids (HYB) derived from the fusion of the volunteer's PBMC with FOl-12 cells. Daudi cells not loaded with peptide are used as a control for lymphokine-activated killing. Lysis with effecto ⁇ target ratios of 1 :1 and 5:1 are shown.
- PBMC peripheral blood mononuclear cells
- A) no antigen B) irradiated, semiallogeneic hybrids
- Target cells for these experiments were: 1) unloaded T2 cells; 2) T2 cells loaded with FLU-MI peptide; 3) T2 cells loaded with GAG peptide; 4) Daudi cells (Fig. 11).
- Fig. 11 results of cytotoxicity assays ( 51 Cr release) showing % lysis values of T2 target cells loaded with HLA-A2-restricted exogenous peptides (FLU-MI or HIV-1 -derived GAG). Unloaded T2 cells and Daudi cells were used as controls.
- Each panel (A-F) represents PBMC effector cells from an HIV-infected, HLA-A2 + patient that have been exposed to: A) no antigen; B) inadiated, semi-allogeneic hybrids (HYB); C) FLU-MI peptide; D) FLU-MI peptide plus inadiated, semi-allogeneic hybrids; E) GAG peptide; or F) GAG peptide plus inadiated, semi-allogeneic hybrids. Lysis with effecto ⁇ target ratios of 1 : 1 and 5 : 1 are shown.
- Shearer GM HIV- induced immunopathogenesis. Immunity 1998, 9:587- 593.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48016/00A AU4801600A (en) | 1999-06-16 | 2000-04-24 | Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1997/015920 WO1998011202A1 (en) | 1996-09-10 | 1997-09-10 | Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids |
US25455699A | 1999-06-16 | 1999-06-16 | |
US09/254,556 | 1999-06-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000076537A2 true WO2000076537A2 (en) | 2000-12-21 |
WO2000076537A3 WO2000076537A3 (en) | 2001-05-03 |
Family
ID=26792754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/011008 WO2000076537A2 (en) | 1997-09-10 | 2000-04-24 | Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2000076537A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074338A1 (en) * | 2001-03-16 | 2002-09-26 | Gsf-Forschungsgesellschaft Für Umwelt Und Gesundheit Gmbh | Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
US8697854B2 (en) | 2008-11-24 | 2014-04-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273716A2 (en) * | 1986-12-30 | 1988-07-06 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins |
WO1991009869A1 (en) * | 1990-01-05 | 1991-07-11 | Medical Research Council | Hiv-1 core protein fragments |
WO1993019775A1 (en) * | 1992-03-31 | 1993-10-14 | Medimmune, Inc. | Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins |
WO1998011202A1 (en) * | 1996-09-10 | 1998-03-19 | Medical University Of South Carolina | Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids |
WO1998033527A2 (en) * | 1997-01-31 | 1998-08-06 | Cohen Edward P | Cancer immunotherapy with semi-allogeneic cells |
-
2000
- 2000-04-24 WO PCT/US2000/011008 patent/WO2000076537A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273716A2 (en) * | 1986-12-30 | 1988-07-06 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins |
WO1991009869A1 (en) * | 1990-01-05 | 1991-07-11 | Medical Research Council | Hiv-1 core protein fragments |
WO1993019775A1 (en) * | 1992-03-31 | 1993-10-14 | Medimmune, Inc. | Administration of liposomes containing peptides or proteins including ctl eptitopes of hiv proteins |
WO1998011202A1 (en) * | 1996-09-10 | 1998-03-19 | Medical University Of South Carolina | Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids |
WO1998033527A2 (en) * | 1997-01-31 | 1998-08-06 | Cohen Edward P | Cancer immunotherapy with semi-allogeneic cells |
Non-Patent Citations (4)
Title |
---|
GRENE E. ET AL.: "Alloimunization for immune based therapy in AIDS malignancies" JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES., vol. 21, 1 May 1999 (1999-05-01), page a16 XP000974801 NEW YORK US * |
HOSMALIN A. ET AL.: "Priming with T helper cell epitopes enhances the antibody response to the envelope glycoprotein of HIV-1 in primates" JOURNAL OF IMMUNOLOGY., vol. 146, 1991, pages 1667-1673, XP000971372 BALTIMORE US ISSN: 0022-1767 * |
NEWTON D.A. ET AL.: "Semiallogeneic cell hybrids as therapeutic vaccines for cancer" JOURNAL OF IMMUNOTHERAPY., vol. 23, March 2000 (2000-03), pages 246-254, XP000971375 NEW YORK US ISSN: 1053-8550 * |
SHEARER G M ET AL: "Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS" IMMUNOLOGY TODAY, vol. 20, no. 2, February 1999 (1999-02), pages 66-71, XP004157278 CAMBRIDGE GB ISSN: 0167-5699 cited in the application * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002074338A1 (en) * | 2001-03-16 | 2002-09-26 | Gsf-Forschungsgesellschaft Für Umwelt Und Gesundheit Gmbh | Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
US8206701B2 (en) | 2001-03-16 | 2012-06-26 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US9238063B2 (en) | 2001-03-16 | 2016-01-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundlheit und Umwelt (GmbH) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US9597384B2 (en) | 2001-03-16 | 2017-03-21 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Semi-allogenic anti-tumour vaccine with HLA haplo-identical antigen-presenting cells |
US8697854B2 (en) | 2008-11-24 | 2014-04-15 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh | High affinity T cell receptor and use thereof |
US9862755B2 (en) | 2008-11-24 | 2018-01-09 | Max-Delbrueck-Centrum Fuer Molekulare Medizin | High affinity T cell receptor and use thereof |
US10626159B2 (en) | 2008-11-24 | 2020-04-21 | Max-Delbrueck-Centrum Fuer Molekulare Medizin | High affinity T cell receptor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2000076537A3 (en) | 2001-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7670611B2 (en) | Cancer immunotherapy with semi-allogeneic cells | |
US8932855B2 (en) | Immune Modulating Exosomes | |
Salgaller et al. | Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide | |
JP3834059B2 (en) | Dendritic cell fixation using v-myc oncogene | |
US20180085398A1 (en) | Compositions and methods of treating cancer | |
WO1997022349A1 (en) | Methods for in vivo t cell activation by antigen-pulsed dendritic cells | |
US20090081127A1 (en) | Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response | |
Matis et al. | Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. | |
EP0839044B1 (en) | Dendritic-like cell/tumor cell hybrids for inducing an anti-tumor response | |
US20180078626A1 (en) | Compositions and methods of treating renal cell cancer | |
CA2977754A1 (en) | Compositions and methods of treating multiple myeloma | |
AU735083B2 (en) | Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and AIDS | |
JP5054875B2 (en) | Cytotoxic T lymphocytes activated by dendritic cell hybrids | |
WO2000076537A2 (en) | Use of semi-allogeneic cell line-peptide complexes for the treatment of cancer, aids and other viral diseases | |
TW201927812A (en) | Pharmaceutical chimeric receptor composition and method thereof | |
Plata | Specificity studies on cytolytic T lymphocytes directed against murine leukemia virus-induced tumors. Analysis of monoclonal cytolytic T lymphocytes. | |
Newton et al. | Semiallogeneic cell hybrids as therapeutic vaccines for cancer | |
Grene et al. | Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes | |
US7740855B2 (en) | Inactivated CD8+ T-cells for the treatment of HIV infection | |
Vyakarnam et al. | T cell responses to peptides covering the gag p24 region of HIV-1 occur in HIV-1 seronegative individuals | |
JPH09507643A (en) | Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic T cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1999 254556 Date of ref document: 19990616 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |